William A. Molina Arocho

William A. Molina Arocho

Auto-generated profile, based on publicly available information

William A. Molina Arocho

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
IFIan W. Folkert
Ian W. Folkert
WAWilliam A. Molina Arocho
William A. Molina Arocho
TTTsun Ki Jerrick To
Tsun Ki Jerrick To
SDSamir Devalaraja
Samir Devalaraja
IMIrene S. Molina
Irene S. Molina
MHMalay Haldar
Malay Haldar
We define a subset of macrophages in the tumor microenvironment characterized by high intracellular iron and enrichment of heme and iron metabolism genes. These iron-rich tumor-associated macrophages (iTAMs) supported angiogenesis and immunosuppression in the tumor microenvironment and were conserved between mice and humans. iTAMs comprise two additional subsets based on gene expression profile and location—perivascular (pviTAM) and stromal (stiTAM). We identified the endothelin receptor type B (Ednrb) as a specific marker of iTAMs and found myeloid-specific deletion of Ednrb to reduce tumor growth and vascular density. Further studies identified the transcription factor Bach1 as a repressor of the iTAM transcriptional program, including Ednrb expression. Heme is a known inhibitor of Bach1, and, correspondingly, heme exposure induced Ednrb and iTAM signature genes in macrophages. Thus, iTAMs are a distinct macrophage subset regulated by the transcription factor Bach1 and characterized by Ednrb-mediated immunosuppressive and angiogenic functions.

1 January 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LXLulu Xue
Lulu Xue
XXXinhong Xiong
Xinhong Xiong
GZGan Zhao
Gan Zhao
WMWilliam Molina-Arocho
William Molina-Arocho
RPRohan Palanki
Rohan Palanki
MMMichael Mitchell
Michael Mitchell

4 December 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Globally, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related death. We previously identified an immune evasion pathway whereby tumor cells produce retinoic acid (RA) to promote differentiation of intratumoral monocytes into protumor macrophages. Retinaldehyde dehydrogenase 1 (RALDH1), RALDH2, and RALDH3 are the three isozymes that catalyze RA biosynthesis. In this study, we have identified RALDH1 as the key driver of RA production in HCC and demonstrated the efficacy of RALDH1-selective inhibitors (Raldh1-INH) in suppressing RA production by HCC cells. Raldh1-INH restrained tumor growth in multiple mouse models of HCC by reducing the number and tumor-supporting functions of intratumoral macrophages as well as increasing T-cell infiltration and activation within tumors. Raldh1-INH also displayed favorable pharmacokinetic, pharmacodynamic, and toxicity profiles in mice thereby establishing them as promising new drug candidates for HCC immunotherapy.

2 February 2024
Verified
Other
Open access
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Supplementary Figure S1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

2 February 2024
Verified
Other
Open access
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Supplementary Figure S2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

2 February 2024
Verified
Other
Open access
PDF file
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Tissue pharmacokinetics and bio-distribution of C86 at two different does through the intraperitoneal route.